ES2634705T3 - Identificación de antígenos de superficie celular, asociados a tumor para diagnóstico y terapia - Google Patents
Identificación de antígenos de superficie celular, asociados a tumor para diagnóstico y terapia Download PDFInfo
- Publication number
- ES2634705T3 ES2634705T3 ES10009753.4T ES10009753T ES2634705T3 ES 2634705 T3 ES2634705 T3 ES 2634705T3 ES 10009753 T ES10009753 T ES 10009753T ES 2634705 T3 ES2634705 T3 ES 2634705T3
- Authority
- ES
- Spain
- Prior art keywords
- associated antigen
- tumor associated
- tumor
- nucleic acid
- amino acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract description 35
- 239000000427 antigen Substances 0.000 title abstract description 34
- 108091007433 antigens Proteins 0.000 title abstract description 34
- 102000036639 antigens Human genes 0.000 title abstract description 34
- 210000004027 cell Anatomy 0.000 title description 3
- 238000003745 diagnosis Methods 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 abstract description 14
- 102000039446 nucleic acids Human genes 0.000 abstract description 14
- 150000007523 nucleic acids Chemical class 0.000 abstract description 14
- 150000001413 amino acids Chemical class 0.000 abstract description 8
- 230000000692 anti-sense effect Effects 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 14
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000003993 interaction Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 238000010200 validation analysis Methods 0.000 description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000012405 in silico analysis Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 108700025694 p53 Genes Proteins 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10344799A DE10344799A1 (de) | 2003-09-26 | 2003-09-26 | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
| DE10344799 | 2003-09-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2634705T3 true ES2634705T3 (es) | 2017-09-28 |
Family
ID=34306102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10009753.4T Expired - Lifetime ES2634705T3 (es) | 2003-09-26 | 2004-09-23 | Identificación de antígenos de superficie celular, asociados a tumor para diagnóstico y terapia |
Country Status (8)
| Country | Link |
|---|---|
| US (6) | US7875424B2 (enExample) |
| EP (22) | EP2266608B1 (enExample) |
| JP (5) | JP5144933B2 (enExample) |
| AU (1) | AU2004275500B2 (enExample) |
| CA (4) | CA2539837C (enExample) |
| DE (1) | DE10344799A1 (enExample) |
| ES (1) | ES2634705T3 (enExample) |
| WO (1) | WO2005030250A2 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10344799A1 (de) | 2003-09-26 | 2005-04-14 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
| WO2005030955A1 (ja) * | 2003-09-29 | 2005-04-07 | Chugai Seiyaku Kabushiki Kaisha | Nk細胞に発現するタンパク質 |
| DE10347710B4 (de) | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Rekombinante Impfstoffe und deren Verwendung |
| DE102005013846A1 (de) * | 2005-03-24 | 2006-10-05 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
| WO2007013575A2 (en) * | 2005-07-28 | 2007-02-01 | Oncotherapy Science, Inc. | Method for diagnosing and treating renal cell carcinoma |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| US8404810B2 (en) * | 2006-02-17 | 2013-03-26 | Five Prime Therapeutics, Inc. | Compositions and methods of use for modulators of polypeptides and polynucleotides in treating breast cancer and melanoma |
| EP2060583A1 (en) | 2007-10-23 | 2009-05-20 | Ganymed Pharmaceuticals AG | Identification of tumor-associated markers for diagnosis and therapy |
| EP2361988B1 (en) | 2008-10-27 | 2016-04-13 | Sapporo Medical University | Molecular marker for cancer stem cell |
| EP2493916B1 (en) | 2009-10-26 | 2016-06-08 | Externautics S.p.A. | Lung tumor markers and methods of use thereof |
| US20130022983A1 (en) | 2009-10-26 | 2013-01-24 | Externautics S.P.A. | Colon and Rectal Tumor Markers and Methods of Use Thereof |
| EP2493917B8 (en) | 2009-10-26 | 2020-03-04 | Externautics S.P.A. | Breast tumor markers and methods of use thereof |
| US8921058B2 (en) | 2009-10-26 | 2014-12-30 | Externautics Spa | Prostate tumor markers and methods of use thereof |
| US10288617B2 (en) * | 2009-10-26 | 2019-05-14 | Externautics Spa | Ovary tumor markers and methods of use thereof |
| FR2973380B1 (fr) * | 2011-04-01 | 2018-02-09 | C.Ris Pharma | Peptides isoles et purifies a partir de testicules de roussette |
| MX360823B (es) | 2011-05-24 | 2018-11-16 | Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh | Vacunas individualizadas para el cancer. |
| TW201302800A (zh) * | 2011-06-10 | 2013-01-16 | Oncotherapy Science Inc | Ｓｅｍａ５ｂ胜肽及含其之疫苗 |
| WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| JP6484558B2 (ja) | 2012-11-28 | 2019-03-13 | バイオエヌテック エールエヌアー ファーマシューティカルズ ゲーエムベーハーＢｉｏｎｔｅｃｈ Ｒｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｇｍｂｈ | 癌ワクチンの組み合せ物 |
| BR112015012234A2 (pt) * | 2012-12-04 | 2017-08-15 | Oncotherapy Science Inc | Peptídios sema5b e vacinas contendo os mesmos |
| WO2014180490A1 (en) | 2013-05-10 | 2014-11-13 | Biontech Ag | Predicting immunogenicity of t cell epitopes |
| EP3194970B1 (en) | 2014-09-10 | 2021-07-28 | F. Hoffmann-La Roche AG | Immunogenic mutant peptide screening platform |
| WO2016045732A1 (en) | 2014-09-25 | 2016-03-31 | Biontech Rna Pharmaceuticals Gmbh | Stable formulations of lipids and liposomes |
| WO2016128060A1 (en) | 2015-02-12 | 2016-08-18 | Biontech Ag | Predicting t cell epitopes useful for vaccination |
| WO2017059902A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
| GB201520564D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| CN108601731A (zh) | 2015-12-16 | 2018-09-28 | 磨石肿瘤生物技术公司 | 新抗原的鉴别、制造及使用 |
| WO2018224166A1 (en) | 2017-06-09 | 2018-12-13 | Biontech Rna Pharmaceuticals Gmbh | Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy |
| EP4576103A3 (en) | 2017-10-10 | 2025-08-27 | Gritstone bio, Inc. | Neoantigen identification using hotspots |
| EP3714275A4 (en) | 2017-11-22 | 2021-10-27 | Gritstone bio, Inc. | REDUCTION OF JUNCTION EPITOPIC PRESENTATION FOR NEOANTIGENS |
| US20200040103A1 (en) | 2018-03-14 | 2020-02-06 | Genentech, Inc. | Anti-klk5 antibodies and methods of use |
| US20250161411A1 (en) * | 2021-12-27 | 2025-05-22 | Memorial Sloan-Kettering Cancer Center | Tumor mhc class i expression is associated with interleukin-2 response in melanoma |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9019812D0 (en) | 1990-09-11 | 1990-10-24 | Scotgen Ltd | Novel antibodies for treatment and prevention of infection in animals and man |
| AU7516494A (en) * | 1993-07-29 | 1995-02-28 | Isis Pharmaceuticals, Inc. | Oligomers for modulating human immunodeficiency virus |
| US5677139A (en) | 1995-04-21 | 1997-10-14 | President And Fellows Of Harvard College | In vitro differentiation of CD34+ progenitor cells into T lymphocytes |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| CA2243235C (en) | 1996-01-17 | 2010-08-10 | Imperial College Innovations Limited | Immunotherapy using cytotoxic t lymphocytes (ctl) |
| SE508004C2 (sv) | 1996-08-07 | 1998-08-10 | Intermec Ptc Ab | Arrangemang för automatisk inställning av printrar samt material därtill |
| JP2002514073A (ja) * | 1997-02-24 | 2002-05-14 | ジェネティックス・インスチチュート・インコーポレーテッド | 分泌蛋白およびそれらをコードするポリヌクレオチド |
| EP0984984A2 (en) * | 1997-06-03 | 2000-03-15 | Sagami Chemical Research Center | HUMAN PROTEINS HAVING TRANSMEMBRANE DOMAINS AND DNAs ENCODING THESE PROTEINS |
| AU764441B2 (en) * | 1998-02-09 | 2003-08-21 | Genset S.A. | cDNAs encoding secreted proteins |
| CA2354369A1 (en) * | 1998-12-22 | 2000-06-29 | Genset S.A. | Complementary dna's encoding proteins with signal peptides |
| AU5559400A (en) * | 1999-06-25 | 2001-01-31 | Serono Genetics Institute S.A. | Complementary dna's encoding proteins with signal peptides |
| CA2393616A1 (en) * | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| WO2001060860A2 (en) * | 2000-02-17 | 2001-08-23 | Millennium Predictive Medicine, Inc. | Genes differentially expressed in human prostate cancer and their use |
| WO2001077292A2 (en) * | 2000-04-07 | 2001-10-18 | Senomyx, Inc. | Novel signal transduction molecules |
| CA2408134A1 (en) * | 2000-05-18 | 2001-11-22 | Incyte Genomics, Inc. | G-protein coupled receptors |
| JP2002112793A (ja) * | 2000-08-04 | 2002-04-16 | Japan Science & Technology Corp | 新規ｇ蛋白質共役受容体 |
| WO2002012343A2 (en) * | 2000-08-07 | 2002-02-14 | Curagen Corporation | Proteins and nucleic acids encoding g-protein coupled receptors |
| EP1326973A2 (en) * | 2000-10-04 | 2003-07-16 | Bayer Aktiengesellschaft | Regulation of human gpcr-like protein |
| WO2002068579A2 (en) | 2001-01-10 | 2002-09-06 | Pe Corporation (Ny) | Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof |
| US7171311B2 (en) * | 2001-06-18 | 2007-01-30 | Rosetta Inpharmatics Llc | Methods of assigning treatment to breast cancer patients |
| WO2003025148A2 (en) * | 2001-09-19 | 2003-03-27 | Nuvelo, Inc. | Novel nucleic acids and polypeptides |
| KR20050008644A (ko) * | 2001-12-21 | 2005-01-21 | 엘지 바이오메디컬 인스티튜트 | 위암에서의 유전자 발현 프로파일 |
| GB0203419D0 (en) * | 2002-02-13 | 2002-04-03 | Oxford Biomedica Ltd | Peptide |
| US20030170639A1 (en) * | 2002-03-11 | 2003-09-11 | Youmin Shu | Liver transmembrane protein gene |
| DE10211088A1 (de) * | 2002-03-13 | 2003-09-25 | Ugur Sahin | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| EP2261368A1 (en) * | 2002-03-13 | 2010-12-15 | Genomic Health, Inc. | Gene expression profiling in biopsied tumor tissues |
| DE10254601A1 (de) * | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| AU2003263660A1 (en) * | 2003-08-29 | 2005-03-16 | Pantarhei Bioscience B.V. | Prenatal diagnosis of down syndrome by detection of fetal rna markers in maternal blood |
| DE10344799A1 (de) | 2003-09-26 | 2005-04-14 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
-
2003
- 2003-09-26 DE DE10344799A patent/DE10344799A1/de not_active Withdrawn
-
2004
- 2004-09-23 EP EP10009743.5A patent/EP2266608B1/de not_active Expired - Lifetime
- 2004-09-23 EP EP10009758A patent/EP2266616A3/de not_active Withdrawn
- 2004-09-23 CA CA2539837A patent/CA2539837C/en not_active Expired - Lifetime
- 2004-09-23 JP JP2006527354A patent/JP5144933B2/ja not_active Expired - Lifetime
- 2004-09-23 EP EP10009750.0A patent/EP2266612B1/de not_active Expired - Lifetime
- 2004-09-23 EP EP04786996.1A patent/EP1664113B1/de not_active Expired - Lifetime
- 2004-09-23 US US10/573,229 patent/US7875424B2/en active Active
- 2004-09-23 EP EP10009763A patent/EP2272534A3/de not_active Withdrawn
- 2004-09-23 EP EP10009760A patent/EP2267014A3/de not_active Withdrawn
- 2004-09-23 EP EP10009744A patent/EP2266609A3/de not_active Withdrawn
- 2004-09-23 EP EP10009755A patent/EP2332981A3/de not_active Withdrawn
- 2004-09-23 CA CA2814269A patent/CA2814269C/en not_active Expired - Lifetime
- 2004-09-23 EP EP10009754.2A patent/EP2267013B1/de not_active Expired - Lifetime
- 2004-09-23 EP EP10009749A patent/EP2266611A3/de not_active Withdrawn
- 2004-09-23 EP EP10009746A patent/EP2267011A3/de not_active Withdrawn
- 2004-09-23 EP EP10009752A patent/EP2266614A3/de not_active Withdrawn
- 2004-09-23 EP EP10009762A patent/EP2332983A3/de not_active Withdrawn
- 2004-09-23 EP EP10009756A patent/EP2332980A3/de not_active Withdrawn
- 2004-09-23 EP EP10009761A patent/EP2266618A3/de not_active Withdrawn
- 2004-09-23 EP EP10009753.4A patent/EP2267012B1/de not_active Expired - Lifetime
- 2004-09-23 EP EP10009757A patent/EP2266615A3/de not_active Withdrawn
- 2004-09-23 CA CA2984653A patent/CA2984653C/en not_active Expired - Lifetime
- 2004-09-23 EP EP10009751.8A patent/EP2266613B1/de not_active Expired - Lifetime
- 2004-09-23 AU AU2004275500A patent/AU2004275500B2/en not_active Expired
- 2004-09-23 WO PCT/EP2004/010697 patent/WO2005030250A2/de not_active Ceased
- 2004-09-23 EP EP10009748A patent/EP2332979A3/de not_active Withdrawn
- 2004-09-23 CA CA3096188A patent/CA3096188C/en not_active Expired - Lifetime
- 2004-09-23 ES ES10009753.4T patent/ES2634705T3/es not_active Expired - Lifetime
- 2004-09-23 EP EP10009747A patent/EP2295077A3/de not_active Withdrawn
- 2004-09-23 EP EP10009745A patent/EP2266610A3/de not_active Withdrawn
- 2004-09-23 EP EP10009759A patent/EP2266617A3/de not_active Withdrawn
-
2010
- 2010-12-16 US US12/969,754 patent/US20110135640A1/en not_active Abandoned
-
2011
- 2011-11-21 JP JP2011253535A patent/JP5639989B2/ja not_active Expired - Lifetime
-
2012
- 2012-10-09 JP JP2012223869A patent/JP5804519B2/ja not_active Expired - Lifetime
-
2013
- 2013-04-16 US US13/863,780 patent/US9139880B2/en not_active Expired - Lifetime
-
2014
- 2014-06-02 JP JP2014113690A patent/JP5969538B2/ja not_active Expired - Lifetime
-
2015
- 2015-08-19 US US14/830,506 patent/US9267177B2/en not_active Expired - Lifetime
- 2015-09-09 US US14/849,052 patent/US9733251B2/en not_active Expired - Lifetime
-
2016
- 2016-02-18 US US15/046,700 patent/US9910043B2/en not_active Expired - Lifetime
- 2016-05-10 JP JP2016094337A patent/JP6196350B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2634705T3 (es) | Identificación de antígenos de superficie celular, asociados a tumor para diagnóstico y terapia | |
| RU2360923C2 (ru) | Новый лиганд рецептора цитокина zcytor17 | |
| ES2625316T3 (es) | Neuquinasa, una proteína corriente abajo de neuregulina | |
| CN101932609A (zh) | 用以调节细胞膜重封的组合物和方法 | |
| JP2010029207A (ja) | ＨＭＧ蛋白質（ｈｉｇｈｍｏｂｉｌｉｔｙｇｒｏｕｐｐｒｏｔｅｉｎ）遺伝子の核酸配列およびそれらの使用 | |
| JP2001518287A (ja) | アポトーシス関連化合物およびその使用 | |
| ES2424976T3 (es) | Isoformas relativas al cáncer de componentes de complejos de factores de transcripción como biomarcadores y dianas de fármacos | |
| US7094569B2 (en) | Hair follicle growth factor proteins | |
| JPH05502789A (ja) | ムチンヌクレオチド | |
| RU2535971C2 (ru) | Тимус-специфический белок | |
| EP3583117B1 (en) | In vitro method for fusing two or more cells, in vitro, method for delivering a gene of interest, and pharmaceutical composition for use in the treatment of a disease | |
| EP3397961A1 (en) | Methods for identifying and treating hemoglobinopathies | |
| US20030220249A1 (en) | Factors for angiogenesis, vasculogenesis, cartilage formation, bone formation, and methods of use thereof | |
| KR20070073802A (ko) | Ｗｎｔ 단백질 및 암의 검출 및 치료 | |
| ES2401233T3 (es) | Isoformas del receptor tipo 5 de somatostatina humana producidas por tratamiento alternativo y pares de oligonucleótidos para la detección de las mismas por PCR | |
| KR101947902B1 (ko) | 간 섬유화 예방 또는 치료용 재조합 단백질 및 이를 포함하는 간 섬유화 예방 또는 치료용 조성물 | |
| KR20050092366A (ko) | 펩티드, 이에 대한 항체, 및 중추 신경계 손상의 치료에있어서의 이의 용도 | |
| WO2006008542A1 (en) | Cell cycle phase markers | |
| CN110713544B (zh) | 融合基因plekha6-ntrk3及其在lch中的应用 | |
| CN114921552B (zh) | 人脑胶质瘤标志物hsa_circ_0000512及其应用 | |
| US20180334486A1 (en) | Recombinant protein for preventing or treating tissue fibrosis and composition for preventing or treating tissue fibrosis comprising the same | |
| JPWO1997032982A1 (ja) | ヒト接着分子オクルディン | |
| JP7764502B2 (ja) | 環状ＲＮＡ Ｃｉｒｃ－ＡＣＥ２翻訳によるポリペプチド及びその使用 | |
| Khavinson et al. | Peptide regulation of aging: 35-year research experience | |
| JP5648927B2 (ja) | Ｈｌａ結合性ペプチド、それをコードするｄｎａ断片および組み換えベクター |